Showing posts with label Diseases. Show all posts
Showing posts with label Diseases. Show all posts

Friday, 12 July 2013

First-Ever Compendium Of RNA Sequences - An Important Guide To Understanding The Root Of Genetic Diseases

Main Category: Genetics
Also Included In: Autism
Article Date: 12 Jul 2013 - 1:00 PDT Current ratings for:
First-Ever Compendium Of RNA Sequences - An Important Guide To Understanding The Root Of Genetic Diseases
not yet ratednot yet rated

Every cell in an organism's body has the same copy of DNA, yet different cells do different things; for example, some function as brain cells, while others form muscle tissue. How can the same DNA make different things happen? A major step forward has been announced that has implications for our understanding of many genetically-linked diseases, such as autism.

Scientists know that much of what a gene does and produces is regulated after it is turned on. A gene first produces a molecule called RNA, to which tiny proteins called RNA binding proteins (RBPs) bind and control its fate. For instance, some of these proteins cut out parts of the RNA molecule so that it makes a particular protein, while other RBPs help destroy the RNA before it even produces a protein.

But these mechanisms are not well understood because the RNA sequences, which the RBPs bind to, have been so difficult to decipher. To fully understand gene regulation (and disregulation, as in the case of disease), scientists have needed to employ advanced lab techniques and data analysis to identify the patterns of the RNA sequences.

This gap in knowledge motivated a team of researchers co-led by Senior Fellow Tim Hughes (University of Toronto and the Canadian Institute for Advanced Research) to produce the first-ever compendium of RNA-binding sequences, which was published in Nature.

"It took us a long time to generate and analyze the data," explains Hughes. "After spending years developing and perfecting a method, we started looking at all the proteins in humans, fruit flies and other complex organisms that look like they may bind RNA and found which sequences they like to bind to. Our compendium of RNA-binding sequences will become a resource for researchers in this field, and will be especially useful in human genetic analysis."

The team found that humans and fruit flies have similar RBPs, since they derive from a common ancestor, and that in many cases they essentially bind the same sequences. The researchers anticipate that this is the case for proteins in other organisms.

"We looked at just over 200 proteins in total, but can probably infer the preference for tens of thousands of proteins in many other organisms," says Hughes.

In addition, many of the sequences similar across species were at the end of the RNA transcript, which is a region associated with regulation of RNA decay or movement of the RNA to another part of the cell. "This indicates that there is probably more regulation of gene expression itself at the level of stability or destruction of RNA," explains Hughes.

One of the major insights that came out of the team's analyses was about a well-studied protein called RBFOX1, which was already known to have a function in regulating RNA splicing and to be decreased in autism. The team's findings suggest that RBFOX1 has a role in regulating the expression level of nervous-system-related genes in brains with autism, and that it does so by making RNA more stable.

The underlying causes of disease are more complicated than a single gene not working right, says Hughes. He anticipates that the team's compendium will be useful in human genetic analysis.

"What often happens is that scientists identify a genetic variation associated with a disease, but then they don't understand why it leads to the disease. What exactly do these sequence changes cause? If the sequence is in a regulatory region of the RNA, then with our compendium, other scientists will be able to see what protein binds to it. This will give them a better idea of what is being disrupted."

The study was a large collaborative effort, supported in part by CIFAR, that involved Senior Fellows Brendan Frey (U of T) and Andrew Fraser (U of T) and Global Scholar Alumnus Matthew Weirauch (Cincinnati Children's Hospital Medical Center) in CIFAR's Genetic Networks program. Hamed Najafabadi (U of T), a postdoctoral fellow who performed much of the analysis in this study, was partially funded by CIFAR.

"Members of the Genetic Networks program have motivated us to look at roles for RNA-binding proteins causing disregulation of gene expression in disease," says Hughes. "We anticipate that this new knowledge will be valuable to other program members working on specific disorders."

The next steps for the team are to expand their compendium to encompass all complex organisms.

Frey also hopes to take these findings further to build models that will more accurately describe observed gene expression patterns.

"My research focuses on deciphering the regulatory sequences in DNA, which ultimately shape the fate of an RNA molecule," explains Frey. "I hope to take the RNA-binding sequences identified in this paper and use them as tokens to figure out how they act in a regulatory fashion. This will help us better understand human disease by providing insights into how a mutation in DNA affects regulation."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our genetics section for the latest news on this subject.

This work was supported by the U.S. National Institutes of Health, Canadian Institutes of Health Research, National Science and Engineering Research Council of Canada, CIFAR, and Human Frontier Science Program.

Canadian Institute for Advanced Research

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Canadian Institute for Advanced Research. "First-Ever Compendium Of RNA Sequences - An Important Guide To Understanding The Root Of Genetic Diseases." Medical News Today. MediLexicon, Intl., 12 Jul. 2013. Web.
12 Jul. 2013. APA
Canadian Institute for Advanced Research. (2013, July 12). "First-Ever Compendium Of RNA Sequences - An Important Guide To Understanding The Root Of Genetic Diseases." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/263204.php.

Please note: If no author information is provided, the source is cited instead.


'First-Ever Compendium Of RNA Sequences - An Important Guide To Understanding The Root Of Genetic Diseases'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Number Of Annual New Drug Approvals To Treat Neglected Diseases Has Nearly Doubled Between The Early-2000s And 2009-12, According To The Tufts Center

Main Category: Regulatory Affairs / Drug Approvals
Also Included In: Tropical Diseases
Article Date: 12 Jul 2013 - 2:00 PDT Current ratings for:
Number Of Annual New Drug Approvals To Treat Neglected Diseases Has Nearly Doubled Between The Early-2000s And 2009-12, According To The Tufts Center
not yet ratednot yet rated

The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent years, with HIV/AIDS and malaria drugs accounting for 60 percent of the most recent approvals, according to a newly completed analysis from the Tufts Center for the Study of Drug Development.

From 2000 to 2008, an average of 2.6 new drug products-including new molecular entities, vaccines, indications, combinations, and formulations-were approved each year to combat neglected diseases. That number increased to an average of five per year in 2009-12, according to Tufts CSDD.

"The trend in approvals is clearly going in the right direction, but annual R&D spending to treat neglected diseases has leveled off at $3 billion in total, after rising rapidly from 2000 to 2007, which is a cause of concern," said Joshua Cohen, PhD, assistant professor at Tufts CSDD who served as principal investigator on the study.

Cohen noted, "While increased approvals may result in greater access to new medicines, policy makers need to ensure that safe, effective, and easy-to-administer products are adopted by health care systems, that they are affordable, and that they reach the people who need them."

The analysis, reported in the July/August Tufts CSDD Impact Report, released today, is the latest in an ongoing series of studies that track progress in drug development targeting neglected diseases, as well as patient access to existing products through donation programs. Among its other findings:

Public-private partnerships accounted for 50% of new product approvals in 2009-12, up from 46% in 2000-08.The research-based industry's share of sponsorship of neglected disease drug development increased to 44% in 2009-12, from 36% in 2000-08.During 2009-12, drugs to treat HIV/AIDS, malaria, and tuberculosis, known as the "Big Three," accounted for 81% of products in development to treat neglected diseases.

Neglected diseases are typically tropical infections most commonly found in developing countries where the population lacks the income to pay for drug treatments. The lack of purchasing power has dissuaded some drug developers from investing in therapeutics to treat these indications.

Article adapted by Medical News Today from original press release. Source:

Tufts Center for the Study of Drug Development


Visit our regulatory affairs / drug approvals section for the latest news on this subject.

Tufts Center for the Study of Drug Development

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Tufts Center for the Study of Drug Development. "Number Of Annual New Drug Approvals To Treat Neglected Diseases Has Nearly Doubled Between The Early-2000s And 2009-12, According To The Tufts Center." Medical News Today. MediLexicon, Intl., 12 Jul. 2013. Web.
12 Jul. 2013. APA
Tufts Center for the Study of Drug Development. (2013, July 12). "Number Of Annual New Drug Approvals To Treat Neglected Diseases Has Nearly Doubled Between The Early-2000s And 2009-12, According To The Tufts Center." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/263267.php.

Please note: If no author information is provided, the source is cited instead.


'Number Of Annual New Drug Approvals To Treat Neglected Diseases Has Nearly Doubled Between The Early-2000s And 2009-12, According To The Tufts Center'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Keeping People With Neurodegenerative Diseases In Work: Pledge For Action At EU Level, Europe

Main Category: Multiple Sclerosis
Also Included In: Parkinson's Disease;  Alzheimer's / Dementia
Article Date: 12 Jul 2013 - 2:00 PDT Current ratings for:
Keeping People With Neurodegenerative Diseases In Work: Pledge For Action At EU Level, Europe
not yet ratednot yet rated

Member of the European Parliament Angelika Werthmann brought a fresh perspective towards improving the quality of life of over 9 million people living with neurodegenerative diseases (NDDs) in Europe. Following a panel discussion on the challenges of NDDs in the workplace, MEP Werthmann offered to launch and sign a 'Written Declaration' of EU parliamentarians, in order "to give people with neurodegenerative diseases better opportunities within Europe".

Neurodegenerative conditions such as Parkinson's disease, Alzheimer's disease and multiple sclerosis affect people at different stages of their professional lives. Contrary to common belief, one in ten people with Parkinson's gets diagnosed at working age and Alzheimer's disease can affect people well before retirement. As for multiple sclerosis, the diagnosis hits fairly early, with the average age being 29. What all three diseases have in common is that the people affected tend to leave the workplace far earlier than necessitated by their condition. For example, half of those with MS stop working three years after diagnosis and, according to a recent UK survey, 60 per cent of people with Parkinson's are reported to retire from work early.

Representatives from the European Multiple Sclerosis Platform (EMSP), Alzheimer Europe and the European Parkinson's Disease Association (EPDA) - co-organisers of the event - highlighted what could be done to help people stay in work:

Raising awareness - improving understanding and fighting stigma, for instance through education and training of employers and colleagues;Adapting social legislation - offering better protection for people with NDDs and their carers through social legislation, such as improved pension rights;Work place adaptations - allowing people to work with their remaining competencies. For instance, fatigue is a common feature for some NDDs. Many people could continue working if adjustments such as parking spaces, flexible schedules and special resting areas were provided;Early intervention - early access to diagnosis and treatment allows people to remain professionally active.

The commitment of EU parliamentarians should help people with neurodegenerative diseases achieve recognition for the contribution they can make to companies and to the wider culture of the EU. "We are the politicians, we are the stakeholders and we will be asked urgently to take the appropriate steps. I do not think I'm being too optimistic if I aim to have the Written Declaration ready by September-October", Mrs Werthmann pledged.

Appropriate measures also require financial commitment. Two recent developments offer positive perspectives leading up to 2020: the European Commission, Parliament and Council of the European Union agreed in principle to increase the budget for brain research and European leaders promised special funding to boost employment for young people across the EU.

As Shana Pezaro, a young person with MS, underlined in her speech from the panel discussion on neurodegenerative diseases in the workplace, "we're not asking for charity, we're asking for our talent to be put to good use".

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our multiple sclerosis section for the latest news on this subject.

Notes:

Unemployment amongst people with MS in EU27 stands at 55%

Two in five people with MS under the age of 35 can't work or study

MS is diagnosed, in two thirds of the cases, between the most active ages of 20 and 30

Find more useful facts and data here:

http://www.underpressureproject.eu/

http://www.emsp.org/projects/ms-id/160-ms-barometer-2011

European Multiple Sclerosis Platform

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

European Multiple Sclerosis Platform. "Keeping People With Neurodegenerative Diseases In Work: Pledge For Action At EU Level, Europe." Medical News Today. MediLexicon, Intl., 12 Jul. 2013. Web.
12 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Keeping People With Neurodegenerative Diseases In Work: Pledge For Action At EU Level, Europe'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here